Eosinophilic granulomatosis with polyangiitis represents a rare, necrotizing systemic vasculitis that predominantly targets small-to-medium vessels. Historically, clinicians have relied on high-dose systemic glucocorticoids combined with conventional immunosuppressive therapies to achieve disease control. However, long-term steroid therapy introduces substantial iatrogenic morbidity, including osteoporosis, metabolic syndrome, and severe opportunistic infections. Recently, targeted biologic agents targeting eosinophil pathways have transformed clinical practice. Emerging evidence demonstrates that anti-IL-5 therapy in EGPA delivers substantial disease control while drastically curtailing cumulative glucocorticoid exposure.

Mechanistic Rationale for Anti-IL-5 Therapy in EGPA

Interleukin-5 serves as the principal cytokine regulating eosinophil differentiation, maturation, activation, and survival. In patients with active vasculitis, hypereosinophilia drives widespread tissue damage, endothelial necrosis, and microvascular thrombosis. Therefore, interrupting this signaling cascade represents a highly rational therapeutic approach. Clinicians now have two distinct monoclonal antibodies that target this specific inflammatory pathway: mepolizumab and benralizumab.

Mepolizumab binds directly to circulating interleukin-5 with high affinity, thereby preventing its interaction with the eosinophil receptor complex. Consequently, this neutralization shortens eosinophil survival and limits tissue infiltration. In contrast, benralizumab binds specifically to the alpha subunit of the interleukin-5 receptor expressed on eosinophils and basophils. Furthermore, this mechanism engages natural killer cells to trigger antibody-dependent cellular cytotoxicity. As a result, benralizumab induces rapid, near-complete eosinophil depletion in both circulating blood and inflamed peripheral tissues.

Both targeted mechanisms alleviate respiratory and systemic symptoms without causing broad immunosuppression. Moreover, clinical trials demonstrate that suppressing interleukin-5 pathways halts disease progression in refractory asthma and eosinophilic vasculitis. Hence, targeted biologic inhibition provides a precise intervention for this multifaceted disorder.

Real-World Glucocorticoid Sparing and Remission Rates

Clinical management of systemic vasculitis frequently encounters the challenge of steroid dependence. In real-world clinical experience from major tertiary hospitals, biologic therapy demonstrates remarkable efficacy in lowering oral glucocorticoid requirements. For example, recent observational data from Hospital Universitario La Paz evaluated adult patients receiving either mepolizumab or benralizumab over twelve months. At baseline, these individuals required an average prednisone dosage of 15.4 mg daily to suppress their symptoms.

Remarkably, over sixty percent of evaluable patients achieved significant dosage reductions within six months of biologic initiation. Furthermore, by the twelve-month milestone, nearly half of the cohort completely discontinued systemic glucocorticoids. This finding carries immense clinical relevance because sustained steroid cessation mitigates severe cardiovascular, metabolic, and bone-related toxicities.

Additionally, patients maintained stable disease activity despite rapid corticosteroid weaning. Vasculitis relapses remained rare among individuals adhering to scheduled biologic administration. Consequently, these real-world findings mirror the success observed in pivotal randomized clinical trials. Practitioners can therefore anticipate meaningful steroid tapering when introducing interleukin-5 inhibitors in real-world cohorts.

Hematologic Clearance of Peripheral Eosinophils

Peripheral hypereosinophilia represents the hallmark laboratory feature of active eosinophilic granulomatosis. Persistent eosinophilia correlates strongly with end-organ damage, including myocarditis, pulmonary infiltrates, and peripheral neuropathy. Therefore, clinicians monitor absolute eosinophil counts as a primary biomarker of therapeutic responsiveness. In clinical practice, both mepolizumab and benralizumab demonstrate potent, sustained hematologic control.

Following biologic initiation, circulating eosinophil counts decrease abruptly within the first few weeks of therapy. In observational cohorts, patients consistently achieve sustained normalization of peripheral counts at twelve months. Indeed, benralizumab frequently reduces circulating eosinophils to undetectable levels due to its cytotoxic receptor-directed mechanism. Similarly, mepolizumab maintains peripheral counts well within normal ranges by neutralizing circulating cytokines.

Moreover, persistent clearance of circulating eosinophils prevents recurrent microvascular infiltration. Clinicians observe that achieving normal eosinophil thresholds correlates directly with clinical remission and reduced relapse rates. Consequently, serial monitoring of absolute eosinophil counts offers an accessible, reliable method for evaluating biologic response in routine practice.

Managing Concomitant Immunosuppression in Complex Phenotypes

Although targeted biologics achieve excellent disease control, severe vasculitic presentations demand nuanced management. In real-world cohorts, a distinct subset of patients continues to require concomitant immunosuppressive therapy alongside anti-IL-5 biologics. Specifically, patients exhibiting multiorgan vasculitis, active glomerulonephritis, or severe peripheral neuropathy often need ongoing conventional immunosuppression.

Clinicians frequently maintain agents like azathioprine, methotrexate, or mycophenolate mofetil during early biologic treatment. In the La Paz cohort, five patients required continuous immunosuppressive therapy due to complex disease phenotypes. Nevertheless, the remaining patients successfully discontinued background immunosuppressive medications without experiencing clinical flare-ups.

This dichotomy highlights the biological heterogeneity of this systemic vasculitis. Anti-interleukin-5 therapies primarily address eosinophil-driven inflammation, but they may not fully arrest independent vasculitic mechanisms driven by adaptive immune cells. Therefore, treating specialists must carefully evaluate individual organ involvement before attempting full immunosuppressant withdrawal. When treating patients with severe systemic manifestations, a combined therapeutic strategy ensures durable disease remission and protects vital organ function.

Impact on Patient Quality of Life and Respiratory Symptoms

Eosinophilic granulomatosis imposes a heavy burden on patient functional capacity and daily well-being. Chronic sinusitis, nasal polyposis, and severe asthma frequently impair physical functioning, sleep quality, and mental health. Fortunately, real-world data confirm that targeted anti-IL-5 interventions yield meaningful improvements in standardized quality-of-life questionnaires.

Patients report notable relief from upper airway obstruction, wheezing, and exertional dyspnea after starting biologic treatment. Furthermore, reduction of steroid-related adverse effects, such as insomnia, emotional lability, and weight gain, significantly enhances overall vitality. In observational studies, numerical scores across health-related quality-of-life instruments show steady improvements over twelve months of treatment.

Additionally, patients experience fewer severe asthma exacerbations, reducing emergency department visits and unplanned hospital admissions. This functional stabilization enables patients to resume physical activities and occupational duties. Therefore, clinicians should incorporate validated patient-reported outcome measures alongside objective biomarkers when monitoring treatment success.

Clinical Implementation and Treatment Selection in India

In Indian clinical practice, diagnosing and managing eosinophilic vasculitis presents unique diagnostic and socioeconomic challenges. Patients often experience delayed diagnosis because presenting respiratory symptoms mimic common conditions such as refractory bronchial asthma or pulmonary tuberculosis. Consequently, physicians must maintain a high index of suspicion when encountering severe asthma accompanied by marked peripheral hypereosinophilia.

Before initiating targeted biologic therapy, clinicians in India must rule out parasitic infections, fungal diseases, and latent tuberculosis. Furthermore, treatment selection between mepolizumab and benralizumab depends heavily on medication availability, cost considerations, and individual phenotypic features. While mepolizumab possesses formal regulatory approval for vasculitis in many jurisdictions, benralizumab provides an effective alternative for patients with prominent eosinophilic asthma phenotypes.

Moreover, multidisciplinary collaboration between pulmonologists, rheumatologists, and internists remains paramount for optimal patient outcomes. Regular monitoring allows clinicians to taper steroids safely while tracking hematologic parameters. Ultimately, adopting targeted biologics into Indian treatment protocols offers hope for reducing long-term steroid toxicity and improving longevity in affected individuals.

How does anti-IL-5 therapy facilitate oral corticosteroid tapering in EGPA?

Anti-IL-5 therapy directly suppresses eosinophilic inflammation by neutralizing interleukin-5 or blocking its alpha receptor. Consequently, this targeted mechanism controls mucosal inflammation and systemic vascular damage without relying on systemic steroid exposure. Because patients maintain disease stability under biologic coverage, clinicians can safely execute progressive steroid tapering protocols. In clinical cohorts, this approach enables more than half of patients to dramatically lower or even completely discontinue maintenance oral prednisone over twelve months.

Which EGPA patients typically require continued concomitant immunosuppressants?

Patients presenting with multiorgan vasculitic involvement, glomerulonephritis, or recurrent peripheral neuropathy frequently require continued conventional immunosuppressive agents alongside biologics. Although targeted biologics effectively suppress eosinophil-mediated tissue injury, severe systemic manifestations may stem from independent vasculitic cascades. Therefore, physicians often maintain agents such as azathioprine or methotrexate during biologic initiation. As clinical stability becomes established over longitudinal follow-up, specialist teams carefully evaluate whether gradual de-escalation of these immunosuppressants is feasible without provoking relapses.

How do mepolizumab and benralizumab differ in their pharmacological mechanisms?

Mepolizumab is a humanized monoclonal antibody that selectively binds circulating interleukin-5 ligand, preventing it from binding the receptor on eosinophils. In contrast, benralizumab binds directly to the interleukin-5 receptor alpha subunit on eosinophils and basophils. This binding induces antibody-dependent cellular cytotoxicity via natural killer cells, leading to near-complete apoptosis and depletion of target cells. Thus, while both therapeutic strategies suppress eosinophilic inflammation, benralizumab accomplishes deeper depletion within both peripheral circulation and affected tissues.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Arribas EB et al. Clinical experience with anti-interleukin-5 monoclonal antibodies in the treatment of eosinophilic granulomatosis with polyangiitis. Farm Hosp. 2026 Oct 14. doi: undefined. PMID: 42875351.
2. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376(20):1921-1932.
3. Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2024;390(10):911-921.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383.